Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.65 |
| ▸ | PI4KA | P42356 | 3/20 | 0.60 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.60 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.60 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.60 |
| ▸ | AHCY | P23526 | 3/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10015788 | 1.00 | ADORA2A (0.69) | ADORA2AADORA1CYP3A4PI4KAPI4K2B | |
| SCHEMBL28883711 | 0.87 | ADORA2A (0.68) | ADORA2AADORA1CYP3A4PI4KAPI4K2B | |
| SCHEMBL20502333 | 0.87 | ADORA2A (0.68) | ADORA2AADORA1CYP3A4PI4KAPI4K2B | |
| SCHEMBL1249906 | 0.87 | ADORA2A (0.68) | ADORA2AADORA1CYP3A4PI4KAPI4K2B | |
| SCHEMBL19831528 | 0.87 | ADORA2A (0.68) | ADORA2AADORA1CYP3A4PI4KAPI4K2B | |
| SCHEMBL15045890 | 0.86 | CYP3A4 (0.70) | ADORA2AADORA1CYP3A4PI4KAPI4K2B | |
| SCHEMBL3305032 | 0.85 | CYP3A4 (0.68) | ADORA2AADORA1CYP3A4PI4KAPI4K2B | |
| SCHEMBL22131060 | 0.85 | ADORA2A (0.64) | ADORA2AADORA1CYP3A4PI4KAPI4K2B | |
| SCHEMBL15257613 | 0.85 | CYP3A4 (0.68) | ADORA2AADORA1CYP3A4PI4KAPI4K2B | |
| SCHEMBL608687 | 0.85 | CYP3A4 (0.68) | ADORA2AADORA1CYP3A4PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115974921-B | Synthetic tenor Fuwei method | 浙江嘉化新材料有限公司 | 2025-03-14 | — | — | CN | claimed |
| CN-119431450-A | Preparation method of R-9- (2-methoxypropyl) adenine | 浙江工业大学 | 2025-02-14 | — | — | CN | claimed |
| CN-119185331-A | Use of nucleoside reverse transcriptase inhibitors in the preparation of medicaments for preventing and treating premature delivery | 上海交通大学医学院附属仁济医院 | 2024-12-27 | — | — | CN | claimed |
| CN-118005693-A | Preparation method of tenofovir alafenamide fumarate impurity | 安徽贝克制药股份有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-115974921-B | Synthetic tenor Fuwei method | 浙江嘉化新材料有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119510597-A | Separation and detection method for tenofovir and enantiomer | 苏州朗科生物技术股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119431450-A | Preparation method of R-9- (2-methoxypropyl) adenine | 浙江工业大学 | 2025-02-14 | — | — | CN | disclosed |
| CN-119431450-A | Preparation method of R-9- (2-methoxypropyl) adenine | 浙江工业大学 | 2025-02-14 | — | — | CN | disclosed |
| CN-119431450-A | Preparation method of R-9- (2-methoxypropyl) adenine | 浙江工业大学 | 2025-02-14 | — | — | CN | disclosed |
| CN-119185331-A | Use of nucleoside reverse transcriptase inhibitors in the preparation of medicaments for preventing and treating premature delivery | 上海交通大学医学院附属仁济医院 | 2024-12-27 | — | — | CN | disclosed |
| CN-118159266-A | Pharmaceutical combination comprising a capsid protein inhibitor and a reverse transcriptase inhibitor | 正大天晴药业集团股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118005693-A | Preparation method of tenofovir alafenamide fumarate impurity | 安徽贝克制药股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-10092509-B2 | Hypotonic microbicidal formulations and methods of use | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-10-09 | — | — | US | disclosed |
| WO-2018119013-A1 | ANTIVIRAL ALIPHATIC ESTER PRODRUGS OF TENOFOVIR | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| EP-3333173-A1 | METHODS FOR PREPARING ANTI-VIRAL NUCLEOTIDE ANALOGS | Gilead Sciences, Inc. (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-2764002-B1 | METHODS FOR PREPARING ANTI-VIRAL NUCLEOTIDE ANALOGS | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170119662-A1 | HYPOTONIC MICROBICIDAL FORMULATIONS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY | 2017-05-04 | — | — | US | disclosed |
| US-20110132376-A1 | TOPICAL ANTIVIRAL FORMULATIONS | CONRAD (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110120475-A1 | TOPICAL ANTIVIRAL FORMULATIONS | CONRAD (US) | 2011-05-26 | — | — | US | disclosed |
| EP-2283812-A2 | Topical antiviral formulations | GILEAD SCIENCES, INC. (US) | 2011-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110132376-A1 | TOPICAL ANTIVIRAL FORMULATIONS | PNP, TYMP, NT5C2 | ADORA2A 308/4885ADORA1 234/4885CYP3A4 2475/4885 |
| US-20110120475-A1 | TOPICAL ANTIVIRAL FORMULATIONS | PNP, TYMP, NT5C2 | ADORA2A 308/4885ADORA1 234/4885CYP3A4 2475/4885 |
| US-20170119662-A1 | HYPOTONIC MICROBICIDAL FORMULATIONS AND METHODS OF USE | SI, SAMHD1, VIP | ADORA2A 575/4885ADORA1 348/4885CYP3A4 2268/4885 |
| US-10092509-B2 | Hypotonic microbicidal formulations and methods of use | SI, SAMHD1, VIP | ADORA2A 575/4885ADORA1 348/4885CYP3A4 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.